Data generation
The biggest misconceptions about agentic AI readiness
To say there’s movement within the agentic life sciences market would be an understatement. According to seven different market research organizations, the “Agentic AI in clinical trials market” is expected to grow at a compound annual growth rate (CAGR) of anywhere between 12.5% and 43%.
While many sponsors and CROs surveyed want agentic AI operating at some level within their clinical trials, almost none of them think they're ready for it. "Our systems don't talk to each other." "Our data is a mess." "We need a two-year foundation project before we can even think about agents." These aren't fringe concerns, they're the default assumptions in nearly every boardroom conversation about AI adoption.
Here's the problem. Those assumptions are very wrong, and they're costing sponsors real time. While teams wait for the "right" conditions to start, the gap between early movers and everyone else keeps widening. The truth is, readiness isn't a prerequisite for agentic AI, it's a byproduct of starting.
Below, we take on the myths that keep organizations stuck in planning mode, and the facts that show why the window to start is now, not after your data is perfectly clean and your stack is fully unified.
Use Case: Integrating consent data to reduce administrative burden
A top-10 pharmaceutical company was looking to reduce the amount of administrative burden on their clinical trial sites and themselves. The sponsor sought to find a vendor that could use one eConsent system to manage paper and electronic consent. Additionally, they sought to use the central eConsent system to populate the clinical trial sites’ IRB and EDC systems, as well as some internal systems.
Simply digital: Trial technologies help reduce oncology’s burden
With the share of oncology trials continuing to increase, the case for using digital tools in these trials grows with it.
Today, cancer trials are the most commonly researched of all diseases, with their share of clinical trials growing each year. According to research from Tufts CSDD, the number of cancer drugs “has nearly quadrupled since 2000, to 1,489 trials in 2021, up from 421 two decades earlier.”
Tufts CSDD notes that this growth comes as “oncology drug developers are increasingly shifting toward precision medicine, embracing new molecular targets and improvements in genetic sequencing technologies”
Keeping up with ClinOps: Why and how to improve delivery
Medable is joined by Join GSK and Lightship for a panel discussion on how a trial platform as a service can enhance, expedite, and improve the day-to-day operations of clinical operations across the life cycle of a study.